After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
Bryan Johnson injected himself with ketamine, a hallucinogen favored by Elon Musk, for 15 days. He used a helmet from his ...
Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...
IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...
4d
News Medical on MSNExploring ketamine's potential in the fight against treatment-resistant depressionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
The FDA approved Ospomyv and Xbryk ... or myelodysplastic syndrome (MDS). Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder ...
4d
Pharmaceutical Technology on MSNSupernus’s stock sinks after depression drug fails trialThe company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Trump’s “first buddy” Elon Musk made a lively, chaotic and unpredictable appearance at the Conservative Political Action ...
Currently, ketamine is not FDA-approved for treating any psychiatric disorder. A similar drug, the nasal spray Spravato (esketamine), is FDA-approved in combination with an oral antidepressant for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results